CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
©2015 American Association for Cancer Research..
The SDF-1 receptor CXCR4 has been associated with early metastasis and poorer prognosis in breast cancers, especially the most aggressive triple-negative subtype. In line with previous reports, we found that tumoral CXCR4 expression in patients with locally advanced breast cancer was associated with increased metastases and rapid tumor progression. Moreover, high CXCR4 expression identified a group of bone marrow-disseminated tumor cells (DTC)-negative patients at high risk for metastasis and death. The protein epitope mimetic (PEM) POL5551, a novel CXCR4 antagonist, inhibited binding of SDF-1 to CXCR4, had no direct effects on tumor cell viability, but reduced migration of breast cancer cells in vitro. In two orthotopic models of triple-negative breast cancer, POL5551 had little inhibitory effect on primary tumor growth, but significantly reduced distant metastasis. When combined with eribulin, a chemotherapeutic microtubule inhibitor, POL5551 additively reduced metastasis and prolonged survival in mice after resection of the primary tumor compared with single-agent eribulin. Hypothesizing that POL5551 may mobilize tumor cells from their microenvironment and sensitize them to chemotherapy, we used a "chemotherapy framing" dosing strategy. When administered shortly before and after eribulin treatment, three doses of POL5551 with eribulin reduced bone and liver tumor burden more effectively than chemotherapy alone. These data suggest that sequenced administration of CXCR4 antagonists with cytotoxic chemotherapy synergize to reduce distant metastases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Molecular cancer therapeutics - 14(2015), 11 vom: 25. Nov., Seite 2473-85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiang, Jingyu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CXCL12 protein, human |
|---|
| Anmerkungen: |
Date Completed 06.09.2016 Date Revised 30.09.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1158/1535-7163.MCT-15-0252 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM251797244 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM251797244 | ||
| 003 | DE-627 | ||
| 005 | 20231224162756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1535-7163.MCT-15-0252 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0839.xml |
| 035 | |a (DE-627)NLM251797244 | ||
| 035 | |a (NLM)26269605 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xiang, Jingyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2016 | ||
| 500 | |a Date Revised 30.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2015 American Association for Cancer Research. | ||
| 520 | |a The SDF-1 receptor CXCR4 has been associated with early metastasis and poorer prognosis in breast cancers, especially the most aggressive triple-negative subtype. In line with previous reports, we found that tumoral CXCR4 expression in patients with locally advanced breast cancer was associated with increased metastases and rapid tumor progression. Moreover, high CXCR4 expression identified a group of bone marrow-disseminated tumor cells (DTC)-negative patients at high risk for metastasis and death. The protein epitope mimetic (PEM) POL5551, a novel CXCR4 antagonist, inhibited binding of SDF-1 to CXCR4, had no direct effects on tumor cell viability, but reduced migration of breast cancer cells in vitro. In two orthotopic models of triple-negative breast cancer, POL5551 had little inhibitory effect on primary tumor growth, but significantly reduced distant metastasis. When combined with eribulin, a chemotherapeutic microtubule inhibitor, POL5551 additively reduced metastasis and prolonged survival in mice after resection of the primary tumor compared with single-agent eribulin. Hypothesizing that POL5551 may mobilize tumor cells from their microenvironment and sensitize them to chemotherapy, we used a "chemotherapy framing" dosing strategy. When administered shortly before and after eribulin treatment, three doses of POL5551 with eribulin reduced bone and liver tumor burden more effectively than chemotherapy alone. These data suggest that sequenced administration of CXCR4 antagonists with cytotoxic chemotherapy synergize to reduce distant metastases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a CXCL12 protein, human |2 NLM | |
| 650 | 7 | |a Chemokine CXCL12 |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Furans |2 NLM | |
| 650 | 7 | |a Ketones |2 NLM | |
| 650 | 7 | |a POL5551 |2 NLM | |
| 650 | 7 | |a Proteins |2 NLM | |
| 650 | 7 | |a Receptors, CXCR4 |2 NLM | |
| 650 | 7 | |a eribulin |2 NLM | |
| 650 | 7 | |a LR24G6354G |2 NLM | |
| 700 | 1 | |a Hurchla, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Fontana, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Xinming |e verfasserin |4 aut | |
| 700 | 1 | |a Amend, Sarah R |e verfasserin |4 aut | |
| 700 | 1 | |a Esser, Alison K |e verfasserin |4 aut | |
| 700 | 1 | |a Douglas, Garry J |e verfasserin |4 aut | |
| 700 | 1 | |a Mudalagiriyappa, Chidananda |e verfasserin |4 aut | |
| 700 | 1 | |a Luker, Kathryn E |e verfasserin |4 aut | |
| 700 | 1 | |a Pluard, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Ademuyiwa, Foluso O |e verfasserin |4 aut | |
| 700 | 1 | |a Romagnoli, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Tuffin, Gérald |e verfasserin |4 aut | |
| 700 | 1 | |a Chevalier, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Luker, Gary D |e verfasserin |4 aut | |
| 700 | 1 | |a Bauer, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Zimmermann, Johann |e verfasserin |4 aut | |
| 700 | 1 | |a Aft, Rebecca L |e verfasserin |4 aut | |
| 700 | 1 | |a Dembowsky, Klaus |e verfasserin |4 aut | |
| 700 | 1 | |a Weilbaecher, Katherine N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular cancer therapeutics |d 2001 |g 14(2015), 11 vom: 25. Nov., Seite 2473-85 |w (DE-627)NLM122520580 |x 1538-8514 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2015 |g number:11 |g day:25 |g month:11 |g pages:2473-85 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1535-7163.MCT-15-0252 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2015 |e 11 |b 25 |c 11 |h 2473-85 | ||